The current CDC perinatal hepatitis B prevention program, funded through Section 317, is a cost-effective use of resources, but a program that reached all pregnant women would provide additional public health benefits, according to results of a recent analysis.
Carolina Barbosa, PhD, of RTI International, and colleagues evaluated the cost-effectiveness of the perinatal hepatitis B
prevention program (PHBPP) to determine perinatal infections and
childhood infections from infants born to hepatitis B surface antigen
(HBsAg)-positive women, quality-adjusted life-years (QALY), lifetime
costs, and incremental cost per QALY gained.